Lanly Bioscience was founded in August 2020. It is a one-stop biomedical comprehensive organization integrating preclinical efficacy evaluation, in vitro tumor pharmacology, DMPK, Non-GLP toxicology experiments, pharmacological risk assessment and other services. The team has a wealth of practical experience and successful case experience, which will be able to effectively help customers avoid risks in a scientific and reasonable manner. Lanli Bio has advanced scientific research capabilities and scientific research models in the industry, as well as advanced biomedical research and development capabilities and technologies, which can integrate technical resources in the industry.